CLOs on the Move

Radius Health

www.radiuspharm.com

 
Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Julie Bregnard
 Associate Director, Compliance Counsel Profile
Erika Tooman
 SVP, General Counsel Profile
Carrie Hanover-Martin
 Assistant General Counsel Profile
James Harrington
 Vice President- Chief Intellectual Property Counsel Profile
Averi Price
 VP, Chief Compliance Officer Profile

Similar Companies

Visus Therapeutics

Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.

US Eye

Be a part of something bigger. Enhance your eye care practice’s capabilities by partnering with a team that understands your business. Contact us today.

Albireo Pharma

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.

Connecticut Orthopaedics

Connecticut Orthopaedics is a premier team of orthopaedic doctors, surgeons and health care professionals that keep you moving forward with life. Learn more

WuXi AppTec

WuXi AppTec, Inc. is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.